Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia

The authors studied the effects of rasagiline on cognition in a sample of 50 nondemented patients with mild to moderate Parkinson’s disease (PD) using a double-blind, placebo controlled design. Cognition and motor symptoms were assessed at baseline and after 6 months of receiving either rasagiline o...

Full description

Saved in:
Bibliographic Details
Published in:The journal of neuropsychiatry and clinical neurosciences 2017, Vol.29 (1), p.22-25
Main Authors: Frakey, Laura L, Friedman, Joseph H
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Analysis of Variance
Antiparkinson Agents - therapeutic use
Cognition - drug effects
Double-Blind Method
Female
Humans
Indans - therapeutic use
Male
Middle Aged
Monoamine Oxidase Inhibitors - therapeutic use
Neuropsychological Tests
Nootropic Agents - therapeutic use
Parkinson Disease - drug therapy
Parkinson Disease - psychology
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The authors studied the effects of rasagiline on cognition in a sample of 50 nondemented patients with mild to moderate Parkinson’s disease (PD) using a double-blind, placebo controlled design. Cognition and motor symptoms were assessed at baseline and after 6 months of receiving either rasagiline or placebo. Participants receiving rasagiline showed improvement in their motor symptoms of PD compared to participants receiving placebo. No significant changes in performance on neuropsychological measures of cognition were observed between the groups. Rasagiline is an effective treatment for the motor symptoms of PD. Rasagiline did not appear to affect cognition during this 6-month study.
ISSN:0895-0172
1545-7222
DOI:10.1176/appi.neuropsych.15050118